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Health Technology Assessment (HTA) 
is an investigative process that evaluates 
the clinical, economic, ethical, and social 
consequences of using new or existing 
technologies in health, from research and 
development to obsolescence. In Brazil, 
HTA was first mentioned in 1983 during 
an international seminar that convened 
representatives from the Pan American 
Health Organization (PAHO) and the 
Government of Brazil to discuss the po-
litical aspects of HTAs. Topics included 
the questionable effectiveness of technol-
ogies used in health, cost and cost-effec-
tiveness, and the process of technology 
transfer. Since then, these activities have 
played a growing role in academia and 
public policy in Brazil (1–6).
Institutional changes were initiated in 
2000 when the Ministry of Health (MoH), 
the National Agencies for Health Surveil-
lance, and the Regulatory Agency for 
Private Health Insurance and Plans es-
tablished the Department of Science 
and Technology; and then in 2003, when 
they formed the Secretariat of Science, 
Technology, and Strategic Inputs. These 
entities are responsible for policy imple-
mentation related to pharmaceuticals 
and health technology, and are expected 
to foster industrial and scientific devel-
opment within Brazil’s Public Health 
System (SUS). Also in 2003, a Permanent 
HTA Work Group was established to con-
duct studies to support and strengthen 
decision-making related to health tech-
nology (7–10).
Later, in 2006, the Commission for 
the Incorporation of Technologies (the 
Commission) was created and a process 
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flow was established for incorporating 
technologies under the auspices of SUS 
and Supplementary Health System (SHS) 
(1, 9, 10). In the same year, Brazil took a 
decisive move into the most important 
arena for HTA international cooperation 
when Department of Science and Tech-
nology joined the International Net-
work of Agencies in Health Technology 
Assessment (2, 3).
In 2008, the Secretariat of Science, 
Technology, and Strategic Inputs was 
given oversight of the Commission and 
asked to evaluate and recommend the in-
corporation, alteration, or exclusion of 
products for the SUS and SHS procedure 
lists; to propose the revision of therapeu-
tic guidelines; and to order and carry out 
HTA-specific studies (6, 11). The process 
flow for incorporating approved technol-
ogies into the health system was also re-
defined in 2008: proposals could only be 
submitted during two time-periods an-
nually, i.e., in February–March or in 
August–September. In turn, the Com-
mission forwarded the process to the 
Secretariats of the MoH responsible for 
the preliminary analysis and prepared a 
technical report with the assistance of the 
Department of Science and Technology. 
The report was revised by the Commis-
sion, which makes recommendations 
based on the expected impact of a given 
technology on the public health system, 
and a technology’s relevance based on 
the best scientific evidence. These recom-
mendations are countersigned by the 
Secretary of the Science, Technology, and 
Strategic Inputs and forwarded to the 
Minister of Health for deliberation. After 
a decision is made, the process returns to 
the Commission, which sends it to the 
ministerial secretariat responsible for im-
plementing the measures. When rele-
vant, the Minister of Health sends the 
recommendation for analysis and a deci-
sion by the Regulatory Agency for Pri-
vate Health Insurance and Plans (6).
Due to advances in HTA, the updating 
of legislation in the country has had a 
multi-dynamic character. It is important 
to mention that this study took place 
during a period in which both civil soci-
ety and the MoH agreed that change was 
needed. A bill was being submitted to 
Congress that called for alterations to the 
HTA process, and it ultimately culmi-
nated in the enactment of Law 12401/11 
(12, 13).
Other HTA studies support the devel-
opment of evidence-based policies, 
acknowledging that new ways are 
needed for linking the technical and po-
litical dimensions of health care and for 
including civil society in the decision to 
incorporate new technology (6). The 
MoH has pointed to the creation of a new 
linkage between scientific policies and 
public health policy. However, for it to be 
successful, elected officials representing 
their populations must participate in the 
implementation processes, both through 
the organizations that currently exist and 
new ones (14).
Initially, this study aimed to analyze 
the opinions of HTA stakeholders, to 
identify the uncertainties and challenges 
of the process, and to understand what 
strategies were being used to overcome 
these. However, because this study was 
conducted just prior to new legislation 
that implemented significant changes, its 
purpose is most relevant as an historical 
analysis of HTA in Brazil.
MATERIALS AND METHODS
This was a cross-sectional study that 
used a structured questionnaire to inves-
tigate the opinion of a convenience sam-
ple of 200 health system decisionmakers 
in Brazil. The study was carried out in 
accordance with a protocol approved by 
the Research Ethics Committee of the 
Universidade Federal de São Paulo (São 
Paulo, Brazil). It was a 2-part question-
naire. Part 1 sought to identify the socio-
economic, educational, and demographic 
profile of the respondents; Part 2 aimed 
to find collect data on the participants’ 
opinion of the HTA process in Brazil.
The intended sample for the study was 
200 completed questionnaires, a number 
considered adequate for the analysis de-
scribed. A database was created with 893 
electronic addresses of potential partici-
pants, based on the researchers’ profes-
sional contacts, university students, and 
the speakers and participants of events 
held by the Grupo Interdepartamental de 
Economia da Saúde (Interdepartmental 
Group on Health Economics), a research 
unit at the university. Access passwords 
were created and allocated to potential 
participants.
Decisionmakers in the health care 
system were determined according to 
the following inclusion criteria: profes-
sionals who could influence HTA deci-
sions or processes, or whose work could 
be affected by HTA-related decisions; 
over 18 years of age; and mentally and 
physically able to answer the question-
naire. The following exclusion criteria 
was also applied: those who refused to 
participate; whose emails addresses in-
valid; and those with ties to the Interde-
partmental Group on Health Economics, 
e.g., teaching staff, researchers, and/or 
who assisted with this study.
The participants were divided into nine 
group established in advance by the re-
searcher according to data on professions 
available in the databases. These groups 
were: health care providers; health insur-
ance plan administrators; pharmaceuticals 
and device industries; regulatory agencies 
of the MoH and public health depart-
ments; commercial diagnostics laborato-
ries and imaging companies; academia; 
and trade unions and associations of 
health professionals.
The questionnaire was hosted on an In-
ternet platform. A letter of invitation 
along with an access password was sent 
electronically, in a random and balanced 
sequence, to potential participants among 
all nine groups. Reminder e-mails were 
sent every 30 days until a total of 200 
completed questionnaires had been 
submitted.
Descriptive statistics were used to de-
scribe the sample, with chi-square tests 
to study possible associations between 
variables (P = 0.05).
RESULTS
Invitations for study participation 
were sent to 597 professionals, 200 of 
whom responded (response rate of 
33.5%). Table 1 describes the demo-
graphic characteristics of the partici-
pants. Males were 47.0% of the sample. 
The age group most frequently observed 
(n = 74; 37.0%) was those 41–50 years of 
age. Most professionals were physicians 
(n = 83; 41.5%), followed by pharmacists 
(n = 33; 16.5%), and nurses (n = 20; 
10.0%). The majority (n = 101; 50.0%) 
worked in the public health system. In 
relation to the hierarchical level of their 
principal function, 20.0% (n = 40) were 
directors and 26.0% (n = 52) were manag-
ers. Most (n = 166; 83.0%) worked in the 
southeast area of Brazil.
According to Table 1, 60.4% (n = 61) of 
the public sector professionals were 
women and 54.5% (n = 54) of the private 
sector professionals were men. Of those 
who worked in the private sector, 90.9% 
(n = 90) were concentrated in the south-
east and 51.5% (n = 51) were physicians. 
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Of the public health professionals, 12.0% 
(n = 12) worked in the mid-west and 
31.7% (n = 32) were physicians. In both 
sectors, most were in the age group of 
those 41–50 years of age, 34.6% (n = 35) in 
the public sector and 38.4% (n = 38) in 
the private.
As shown in Table 2, most participants 
were of the opinion that: the HTA review 
period was inadequate (n = 170; 85.0%); 
the composition of the Commission for 
HTA review and approval was inade-
quate (n = 176; 88.0%); the entire process 
should take 6–12 months (n = 189; 
85.0%); and specific regulations were 
needed for each type of health technol-
ogy (n = 155; 77.0%).
A comparison of responses by public 
versus private HCS professionals found 
a statistically significant association 
between those in the private services, 
with regard to: the inadequate submis-
sion time period, 92.9% versus 77.2% for 
those from the public services (P = 0.019; 
X2 = 9.967); the evaluation time period as 
defined by the law, 94.9% versus 85.1% 
for the public (P = 0.021; X2 = 5.336); 
an evaluation period < 6 months, 82.8% 
versus 58.4% (P < 0.001; X2 = 14.502); and 
circumstances under which the MoH 
should send the recommendation to 
ANS, 93.9% versus 82.0% (P < 0.001; 
X2 = 6.687). Private health system profes-
sionals wanted the total analysis time, 
from registration to recommendation, 
to be shorter than what those from the 
public health system were requesting, 
54.5% and 37.0% respectively (P < 0.001; 
X2 = 9.909). The responses of profession-
als with ties to government entities and 
those without such ties were also ana-
lyzed (Table 3).
DISCUSSION
Although Brazil has made important 
advances in HTA-related policy discus-
sion, formulation, and legislation, there 
are still many challenges to overcome. 
The assessment process is still perceived 
as slow; its methodology is considered 
incomplete; its scope, insufficient; and its 
capacity, unable to serve the needs of 
the both the public and private health 
systems (4).
Most respondents (85.0%, n = 170) 
considered the allotted timeframe for 
submitting requests to be inadequate, 
and there was a statistically significant 
association between professionals from 
the private health system and this belief 
(P = 0.019; X2 = 9.667). However, since the 
enactment of Law 12401/11, requests can 
be submitted at any time; therefore, the 
feedback captured by this study’s ques-
tionnaire has been satisfactorily addressed 
(12, 13). In addition, the continuous 
workflow means the process has become 
more efficient and faster; over time, this 
could change the perceived “slowness” 
expressed by stakeholders (4).
Regarding the composition of the Com-
mission, 88.0% of respondents stated it 
was inadequate for meeting existing de-
mand. There was a statistically significant 
association between this belief and pro-
fessionals not directly linked to the gov-
ernment (P < 0.001; X2 = 9.909). There may 
be an expectation among this group that 
they should be consulted and/or partici-
pate in the Commission. According to re-
spondents, representatives of professional 
associations, councils, organizations, and 
academia should be part of the Commis-
sion. This finding concurs with a study 
stating that government, academia, and 
specialists are groups that should be in-
cluded in the HTA process (4).
Law 12401/11 replaced the Commis-
sion with the National Commission 
for the Incorporation of Technology 
(CONITEC). CONITEC has 13 mem-
bers, instead of five, including a repre-
sentative from the National Health 
Council and another from the Federal 
Council on Medicine (12, 13, 15). The 
need for public and patient involvement 
in the decision-making process is widely 
recognized given that they stand to ei-
ther benefit or suffer the consequences 
of applying a new health technology; 
TABLE 1. Characteristics of 200 health care professionals responding to a 
questionnaire on the health technology assessment process in Brazil, by type of 
health care employer, 2010–2011
Characteristics
Health care system
Total Public Private
n % n % n %
Gender
 Female 106 53.0 61 60.4 45 45.4
 Male 94 47.0 40 39.6 54 54.5
Age group (years)
 41 – 50 73 37.0 35 34.7 38 38.4
 31 – 40 56 28.0 28 27.7 28 28.3
 51 – 60 37 19.0 20 19.8 17 17.2
 < 30 28 14.0 15 14.8 13 13.1
 > 60 6 3.0 3 3.0 3 3.0 
Geographic area of Brazil
 Southeast 166 83.0 76 75.3 90 90.9
 Center-west 15 7.5 12 11.9 3 3.0 
 South 14 7.0 9 8.9 5 5.1
 Northeast 5 2.5 4 3.9 1 1.0
 North 0 0.0 0 0.0 0 0.0 
Profession
 Physician 83 41.7 32 31.7 51 51.5
 Pharmacist 33 16.6 13 12.9 20 20.2
 Nurse 20 10.1 13 12.9 7 7.1
 Administrator 18 9.0 10 9.9 8 8.1
 Engineer 10 5.0 8 7.9 2 2.0
 Economist 10 5.0 7 6.9 3 3.0
 Other 25 12.6 18 17.8 8 8.1
Main role in health care system
 Manager 72 36.0 26 25.7 46 46.5
 Research 31 15.5 24 23.8 7 7.1
 Service provider/health care 44 22.0 20 19.8 24 24.2
 Technician/ Assistant 21 10.5 16 15.8 5 5.1
 Teaching 10 5.0 8 7.9 2 2.0
 Other 22 11.0 7 6.9 15 15.1
Source: Prepared by the authors from the study data.
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furthermore, CONITEC aims to increase 
transparency and diminish any biases in 
the process (16). Other countries, such 
as Australia, Canada, Germany, and 
the United Kingdom have also made 
changes that involve the participation of 
civil society and medical specialists in 
the HTA process (17–20).
Regarding the time allowed to evalu-
ate requests, the legislation in place at the 
time of this study stated that the Com-
mission should meet pre-established 
deadlines; however, the terms of dead-
lines were not specified. Given this, 
90.0% (n = 180) of participants indicated 
that deadlines should be clearly defined 
and stated specifically by the legislation. 
There was a statistically significant asso-
ciation between professionals in the pri-
vate system and this statement (P = 0.021; 
X2 = 5.336). When asked what the ideal 
time period should be, professionals in 
the public system (P < 0.001; X2 = 14.502) 
and those directly linked with a govern-
ment body (P = 0.032; X2 = 6.874) sug-
gested a longer time period than those in 
the private system proposed; note that 
this association was statistically 
significant.
Possibly, the private sector, which is 
most often making an HTA request, pre-
fers shorter evaluation periods because 
it would benefit from having its prod-
ucts included in SUS and SHS more 
quickly. On the other hand, the public 
system, usually receiving the request, 
has a clearer picture of the real demands 
of the health system, the volume of 
requests pending analysis, and the time 
required to carry out a satisfactory 
evaluation.
Respondents were urged to suggest an 
assessment time-period that would en-
sure that only secure and effective tech-
nologies would be permitted to enter 
Brazil’s health care system. Professionals 
from the private sector and those not di-
rectly linked to the government agreed 
that once a request was registered, the 
evaluation should take no more than 6 
months (P < 0.001; X2 = 9.909; P = 0.002; 
X2 = 12.247, respectively). Again, those 
from the private health sector preferred a 
shorter analysis time, while those in the 
public health system—charged with per-
forming the analyses—preferred a lon-
ger time period.
At the time that the responses were 
collected, the legislation did not stipulate 
the assessment time for processes. The 
new legislation established a period of 
180 days, extendable for another 90 days, 
to analyze processes. This period begins 
on the date of registration, when all re-
quired documents have been submitted, 
and runs through the day that the re-
sponse is provided. Therefore, the 
TABLE 2. Responses from 200 health care professions who completed a questionnaire 
on the Health Technology Assessment (HTA) process in Brazil, 2010–2011
n %
1. Regarding the time period for submission of new requests
  Inadequate. All submissions should obey the same period and should be done 
electronically.
 Inadequate. All submissions should be done throughout the year.
 Adequate
 Inadequate. All submissions should obey the same established period.
92
70
30
8
46.0
35.0
15.0
4.0
2. Regarding the composition of the Commission that evaluates submissions 
 Inadequate.
 Adequate.
176
24
88.0
12.0
3. Regarding the calendar of the Commission that assesses submissions. 
 Both the calendar and the agenda should be announced.
 Just the calendar should be announced.
 Should not be announced.
158
26
16 
79.0
13.0
8.0
4. “The times established for analyses should be defined in the legislation.”
 Agree, 6 months.
 Agree, 3 months.
 Agree, 12 months.
 Do not agree.
 Agree, 9 months.
78
63
28
20
11 
39.0
31.5
14.0
10.0
5.5
5. Referring to the number of votes by which the Commission approves a request. 
 Adequate.
 Should be considered 80% of valid votes.
 Should be by a simple majority.
 Should be by consensus.
82
64
36
16 
41.2
32.2
18.1
8.5
6. On the approval of the Commission’s recommendations.
 Adequate
 Should only be done by the CITECa.
 Should only be done by the Secretary of Science, Technology, and Strategic Inputs.
 Should only be done by the Minister of Health.
101
53
24
22 
50.5
26.5
12.0
11.0
7. “The circumstances under which the Minister of Health submits recommendations for assessment and 
determination by the ANSb should be clearly defined.”
 Agree.
 Disagree.
175
25
87.5
12.5
8. For denying approval of a request: what information should be provided to the applicant? 
 Notification and detailed report.
 Notification and justification.
 Only a notification.
155
40
4 
 77. 9
20.1
2.0
9. Regarding the appeal process/reconsideration of a decision. 
 Inadequate.
 It is adequate.
181
18 
90.9
9.1
10. How long should the entire process take?
 6 months.
 12 months.
 18 months.
 24 months.
 36 months.
91
78
17
9
4 
45.7
39.2
8.5
4.6
2.0
11. “Should there be specific regulations for each type of health technology?”
 Yes.
 No.
155
45 
77.5
22.5
12. Are you aware of the HTA and the incorporation process in Brazil?
 Yes.
 Yes, but vaguely.
 Yes, extensively.
 No.
78
60
45
17 
39.0
30.0
22.5
8.5
Source: Prepared by the authors from the study data.
a Comissão de Incorporação de Tecnologias do Ministério da Saúde (Commission for Incorporating Technology, 
Ministry of Health).
b Agência Nacional de Saúde Suplementar (National Regulatory Agency for Private Health Insurance and Plans).
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maximum period set forth by the law 
and the decree, there is a total of 270 
days. Given this, in Brazil the HTA pro-
cess can take 6 months or less or not 
more than a maximum of 9 months. Aus-
tralia, Canada, and the United Kingdom 
require that analysis to be complete in 
11–18 months (4, 21–23).
Limitations. The research for this study 
was conducted at a time when civil soci-
ety and the MoH agreed that change in 
HTA was needed. It is important to note 
that the study results reflect the attitudes 
that precipitated the new legislation, 
and that the subsequent enactment of 
both the HTA bill and decree would have 
altered eight of its 11 items. Regardless, 
this article has value as an historical anal-
ysis of the HTA process in Brazil (12, 13).
In addition, 91.5% of respondents 
claimed to have some knowledge of the 
HTA process in Brazil. This is not sur-
prising since the study database was 
built with information from HTA-related 
professionals. However, a weakness of 
this strategy is the fact that the sample 
subjects, mostly working in the southeast 
part of the country, might not be repre-
sentative of the various stakeholders’ 
views nationwide. Since the demograph-
ics were only discovered after the data 
collection and analysis, it remains un-
known whether or not this occurred by 
chance. A chi-squared test to evaluate the 
significance of this relationship was not 
performed.
Conclusions
It is a known fact that Brazil lacks the 
number of qualified human resources 
and the institutional dynamics observed 
in more developed countries. Both of 
these challenges can hinder efficient and 
reliable assessments of health technolo-
gies (24). Therefore, the new HTA time-
frames need to be monitored to verify 
that they are sufficiently ample for en-
suring that only reputable, safe, efficient, 
and effective technologies are being of-
fered to society.
TABLE 3. Associations of responses to a questionnaire on the health technology assessment (HTA) process in Brazil, by public 
or private health care systems and between groups with and without a professional connection to any government entity, Brazil, 
2010–2011
Question
Health care system type
P value  
(Chi-square)
Connection with a government entity
P value  
(Chi-square)Public
%
Private
%
Yes
%
No
%
Regarding time period for submission of new requests.
 It is adequate 22.77 7.07 0.019
(9.667)
23.81 8.62 0.0056 
(7.664) It is inadequate 77.23 92.93 76.19 91.38
Regarding the composition of the Commission that evaluates submissions.
 It is adequate 7.34 3.65 NA 12.85 0.39 NA
 It is inadequate 92.66 96.35 87.15 99.61
“The times established for analyses should be defined in the legislation.”
 Disagree 14.85 5.05 0.021
(5.336)
14.29 6.9 NA
 Agree 85.15 94.95 85.71 93.1
“The times established for analyses should be defined in the legislation.”
 Disagree 14.85 5.05 P < 0.001 
(14.502)
14.29 6.9 0.032
(6.874) Agree < 6 months 58.42 82.83 60.71 77.59
 Agree > 6 months 26.73 12.12 25.00 15.52
Announcement of the calendar and the agenda of the Commission
 Should not be announced 10.89 5.05   13.10 4.31 NA
 Only the calendar should be announced 11.88 14.14 NA 10.71 14.66
 Both should be announced 77.23 80.81   76.19 81.06
On the approval of the Commission’s recommendations
 Adequate 57.43 43.43 NA 58.33 44.83 NA
 Should be done by the Secretary or Ministry of Health (MoH) 21.78 24.24 20.24 25.00
 Should be done by the CITECa 20.79 32.32 21.43 30.17
“The circumstances under which the which lead the MoH submit recommendations for assessment and determination by the ANSb should be clearly defined.”
 Agree 82.00 93.94 P < 0.001 
(6.6866)
85.71 89.57 NA
 Disagree 18.00 6.06 14.29 10.43
How long should the entire process should take?
 6 months 37.00 54.55 P < 0.001
(9.909)
32.53 55.17 0.002
(12.2468) 12 months 41.00 37.37 44.58 35.34
 > 12 months 22.00 8.08 22.89 9.48
“Should there be specific regulations for each type of health technology?”
 Yes 76.24 78.79
NA
77.38 77.59
NA
 No 23.76 21.21 22.62 22.41
Source: Prepared by the authors from the study data.
a Comissão de Incorporação de Tecnologias do Ministério da Saúde (Commission for Incorporating Technology, Ministry of Health).
b Agência Nacional de Saúde Suplementar (National Regulatory Agency for Private Health Insurance and Plans).
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One of the most important aspects of 
the new legislation is its call for public 
consultations on technologies being as-
sessed. Although public consultation is 
a way for society to participate in and 
lend more transparency to the decision-
making process, it is still just a democratic 
tool whose success strictly depends on 
the participants’ qualifications, the thor-
oughness of their input, and on their un-
derstanding health system’s needs. 
However, this success should be fol-
lowed over time and maybe probably be 
revised accordingly.
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Objetivos. Describir, analizar y comparar las opiniones de los encargados de adop-
tar las decisiones en el proceso de evaluación de las tecnologías sanitarias llevado 
 adelante en el Brasil durante el 2011. 
Métodos. Se realizó un estudio transversal en el que se administró un cuestionario 
estructurado para evaluar las opiniones de una muestra de conveniencia de profesio-
nales de la salud tanto del sistema público como del privado. La encuesta recopiló los 
datos demográficos de cada encuestado junto con su opinión respecto de los regla-
mentos nacionales. El análisis de los datos incluyó estadísticas descriptivas, como la 
prueba de la ji al cuadrado para comparar los datos de los distintos grupos. 
Resultados. De los 200 encuestados que respondieron el cuestionario, el 65 % tenía 
31–50 años; el 36 % ocupaba algún cargo gerencial en el sistema de salud, el 49,3 % 
pertenecía al público y el 50,7 % trabajaba en el sistema privado. La mayoría de los 
encuestados (85 %) consideraron insuficiente el tiempo permitido para presentar las 
nuevas tecnologías; el 88 % también declaró que debía mejorar la composición del 
comité de evaluación. Los encuestados del sistema de salud privado declararon con 
más frecuencia que los tiempos de presentación habían sido inadecuados (P = 0,019) 
y que era necesario definir un lapso máximo para que el comité tomara su decisión 
(P = 0,021), el que no debía exceder los 180 días o 6 meses (P < 0,001). 
Conclusiones. Los encuestados indicaron que es preciso mejorar el proceso de eva-
luación de las tecnologías sanitarias a fin de satisfacer sus expectativas. En vista de que 
se han aprobado nuevas leyes que habilitan la presentación continua de nuevas tecno-
logías, que imponen la toma de decisiones al cabo de 180 días y que amplían el comité 
para que estén representados más interesados directos, se ha abordado la mayoría de 
las inquietudes manifestadas por los encuestados. Este estudio es valioso como análi-
sis histórico del mejoramiento de los procesos de evaluación de las nuevas tecnolo-
gías. Es preciso emprender más encuestas para llevar a cabo un seguimiento del nuevo 
proceso, su aplicación y su contribución a las necesidades de atención de salud en el 
Brasil. 
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Evaluación de las 
 tecnologías  sanitarias: el 
 proceso vigente en el Brasil
Objetivos: Descrever, analisar e comparar as opiniões dos tomadores de decisão 
envolvidos com o processo de Avaliação de Tecnologias em Saúde (ATS) em vigor no 
Brasil, em 2011.
Métodos. Estudo transversal conduzido através de questionário estruturado para 
avaliar as opniões de uma amostra de conveniência composta de profissionais de saúde 
dos sistemas de saúde público e privado. Foram coletados dados demográficos de todos 
os respondentes junto com suas opiniões sobre as regulamentações nacionais. 
Resultados. Dos 200 questionários completados, 65% dos respondentes tinham entre 
31-50 anos de idade; 36% eram gestores do sistema de saúde: 49.3% do sistema público 
e 50.7% do privado. A maioria dos respondentes (85%) considerou que o tempo per-
mitido para a submissão de novas tecnologias era inadequado; 88% informou que a 
composição do comitê de avaliação necessitava melhorias. Respondentes do sistema 
privado de saúde responderam, com mais frequência, que os tempos de submissão 
eram inadequados (P=0.019) e que o prazo para a decisão pelo comitê deveria ser 
definido (P=0.021), com um prazo não superior a 180 dias/ 6 meses (P<0.001).
Conclusões: Respondentes indicaram que o processo de ATS deveria ser melhorado 
para alcançar suas expectativas. O fato de que uma nova legislação em ATS foi apro-
vada onde se aceitam submissões de forma contínua, tomada de decisões em até 180 
dias, e agregam representantes da sociedade ao comitê de avaliação, demonstra que 
grande parte das preocupações dos respondentes foi respondida. Este estudo tem seu 
valor como uma análise histórica da melhoria do processo de ATS no país. Pesquisas 
adicionais  são necessárias para acompanhar o novo processo de ATS, sua aplicação e 
contribuição às necessidades do sistema de saúde no Brasil.
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